Nikko Asset Management Americas Inc. Sells 67,700 Shares of Pfizer Inc. (PFE)
Nikko Asset Management Americas Inc. decreased its stake in Pfizer Inc. (NYSE:PFE) by 61.5% during the second quarter, Holdings Channel reports. The firm owned 42,441 shares of the biopharmaceutical company’s stock after selling 67,700 shares during the period. Nikko Asset Management Americas Inc.’s holdings in Pfizer were worth $1,486,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Oliver Luxxe Assets LLC boosted its stake in shares of Pfizer by 429.0% in the first quarter. Oliver Luxxe Assets LLC now owns 100,305 shares of the biopharmaceutical company’s stock valued at $2,973,000 after buying an additional 81,343 shares in the last quarter. Howard Capital Management boosted its stake in shares of Pfizer by 1.4% in the first quarter. Howard Capital Management now owns 85,190 shares of the biopharmaceutical company’s stock worth $2,525,000 after buying an additional 1,162 shares during the period. Montrusco Bolton Investments Inc. boosted its stake in shares of Pfizer by 32.2% in the first quarter. Montrusco Bolton Investments Inc. now owns 14,769 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 3,599 shares during the period. Dividend Asset Capital LLC boosted its stake in shares of Pfizer by 31.5% in the first quarter. Dividend Asset Capital LLC now owns 13,844 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,315 shares during the period. Finally, V Wealth Management LLC purchased a new stake in shares of Pfizer during the first quarter worth approximately $272,000. Institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 1.43% on Tuesday, reaching $33.13. 17,331,125 shares of the company traded hands. The stock’s 50-day moving average is $34.25 and its 200-day moving average is $34.28. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The stock has a market capitalization of $200.96 billion, a price-to-earnings ratio of 29.37 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share. Equities research analysts expect that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.62%. Pfizer’s dividend payout ratio is presently 95.24%.
A number of analysts have commented on PFE shares. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a research report on Monday, June 27th. Deutsche Bank AG reaffirmed a “buy” rating and set a $44.00 price target on shares of Pfizer in a research report on Thursday, August 18th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, July 14th. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.